For cancer patients, breakthrough pain (BTP) can appear suddenly, even if they’re already using strong analgesics to manage discomfort.
Our Onsolis (Fentanyl Citrate Buccal Film) is a clinically established option for treating BTP in adult cancer patients. Thin, flexible and discreet, it can be easily applied to the gum where it dissolves without any need for water or swallowing, and without any effervescent sensation.
For patients already managing the demands of cancer treatment, this ease of use is not a minor convenience: it’s a meaningful contribution to quality of life and medication adherence.
To discuss Onsolis or to see our full portfolio of products for pain and oncology, contact a member of the team today.
Designed to deliver quickly
The patented BioErodible MucoAdhesive (BEMA®) bilayer delivery technology enables fast, direct absorption via the buccal mucosa. It bypasses hepatic first-pass metabolism, enabling predictable plasma concentrations and rapid onset of action, both critical for managing BTP, which can be sudden and unpredictable.
Designed for safety
The inner, active layer adheres comfortably to the inner cheek, delivering the active ingredient directly into the bloodstream. Meanwhile, the protective outer layer limits drug loss into saliva. The result is controlled, directional absorption that traditional oral formulations cannot achieve.
The film presentation also reduces misuse potential compared to conventional opioid formulations. This makes it an important consideration for appropriate patient populations and supports responsible prescribing within the broader opioid landscape.
Designed for commerce
Onsolis is already in clinical use across Europe, including Germany, reflecting established regulatory approval and prescriber adoption.
The complexity of BEMA® film technology is a meaningful barrier to generic competition. Available in five strengths (200, 400, 600, 800 and 1200 µg), Onsolis is suited to flexible titration based on individual patient need.
To discuss licensing opportunities, or to explore our full pain portfolio, contact one of the team today.